Literature DB >> 11599333

Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update).

I Olivotto1, M Levine.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11599333      PMCID： PMC81502     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

Review 1.  Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee.

Authors: 
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

2.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

Authors:  B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

Authors:  J P Julien; N Bijker; I S Fentiman; J L Peterse; V Delledonne; P Rouanet; A Avril; R Sylvester; F Mignolet; H Bartelink; J A Van Dongen
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

Review 4.  The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists.

Authors: 
Journal:  CMAJ       Date:  1998-02-10       Impact factor: 8.262

Review 5.  Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Authors:  M Levine; J M Moutquin; R Walton; J Feightner
Journal:  CMAJ       Date:  2001-06-12       Impact factor: 8.262

6.  Waiting times from abnormal breast screen to diagnosis in 7 Canadian provinces.

Authors:  I A Olivotto; C Bancej; V Goel; J Snider; R G McAuley; B Irvine; L Kan; D Mirsky; M J Sabine; R McGilly; J S Caines
Journal:  CMAJ       Date:  2001-08-07       Impact factor: 8.262

7.  The influence of margin width on local control of ductal carcinoma in situ of the breast.

Authors:  M J Silverstein; M D Lagios; S Groshen; J R Waisman; B S Lewinsky; S Martino; P Gamagami; W J Colburn
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

8.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Authors:  B Fisher; J Dignam; N Wolmark; D L Wickerham; E R Fisher; E Mamounas; R Smith; M Begovic; N V Dimitrov; R G Margolese; C G Kardinal; M T Kavanah; L Fehrenbacher; R H Oishi
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321
  8 in total
  11 in total

Review 1.  Tamoxifen for breast cancer prevention: safety warning.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-08-20       Impact factor: 8.262

2.  Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast.

Authors:  Li Wang; Wei Zhang; Shuhua Lyu; Xia Liu; Tongxian Zhang; Shan Liu; Ying Qin; Xiaoqi Tian; Yun Niu
Journal:  Tumour Biol       Date:  2015-03-24

Review 3.  Microinvasive carcinoma of the breast.

Authors:  Simonetta Bianchi; Vania Vezzosi
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

4.  The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study.

Authors:  Vicki Hart; Amy Trentham-Dietz; Amy Berkman; Mayo Fujii; Christopher Veal; John Hampton; Ronald E Gangnon; Polly A Newcomb; Susan C Gilchrist; Brian L Sprague
Journal:  Qual Life Res       Date:  2018-02-07       Impact factor: 4.147

5.  Compliance with guidelines is related to better local recurrence-free survival in ductal carcinoma in situ.

Authors:  M A J de Roos; G H de Bock; P C Baas; L de Munck; T Wiggers; J de Vries
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

6.  Rates and predictors of consideration for adjuvant radiotherapy among high-risk breast cancer patients: a cohort study.

Authors:  Stanimira Krotneva; Kristen Reidel; Mohammed Nassif; Nora Trabulsi; Nancy Mayo; Robyn Tamblyn; Ari N Meguerditchian
Journal:  Breast Cancer Res Treat       Date:  2013-07-24       Impact factor: 4.872

7.  Effect of Referral Patterns and Treatment Type on Oncologic Outcomes for Women with Ductal Carcinoma In Situ.

Authors:  Elaine S Wai; Mary Lesperance; Linghong Lu; Cheryl S Alexander; Pauline T Truong
Journal:  Cureus       Date:  2017-03-31

8.  Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial.

Authors:  Kathryn Ottolino-Perry; Anam Shahid; Stephanie DeLuca; Viktor Son; Mayleen Sukhram; Fannong Meng; Zhihui Amy Liu; Sara Rapic; Nayana Thalanki Anantha; Shirley C Wang; Emilie Chamma; Christopher Gibson; Philip J Medeiros; Safa Majeed; Ashley Chu; Olivia Wignall; Alessandra Pizzolato; Cheryl F Rosen; Liis Lindvere Teene; Danielle Starr-Dunham; Iris Kulbatski; Tony Panzarella; Susan J Done; Alexandra M Easson; Wey L Leong; Ralph S DaCosta
Journal:  Breast Cancer Res       Date:  2021-07-12       Impact factor: 6.466

9.  Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.

Authors:  Nadia P Castro; Cynthia A B T Osório; César Torres; Elen P Bastos; Mário Mourão-Neto; Fernando A Soares; Helena P Brentani; Dirce M Carraro
Journal:  Breast Cancer Res       Date:  2008-10-17       Impact factor: 6.466

Review 10.  A new model for ductal carcinoma in situ suggests strategies for treatment.

Authors:  William John Gullick
Journal:  Breast Cancer Res       Date:  2002-07-19       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.